Printer Friendly

ZAMBON LICENSES FOSFOMYCIN TROMETAMOL TO FOREST LABORATORIES

      ZAMBON LICENSES FOSFOMYCIN TROMETAMOL TO FOREST LABORATORIES
    EAST RUTHERFORD, N.J., Nov. 20 /PRNewswire/ -- Zambon Corporation, the U.S. subsidiary of the multi-national pharmaceutical company Zambon Group SpA of Milan, Italy, announced today that Forest Laboratories (AMEX: FRX) of New York City will be U.S. licensee for fosfomycin trometamol, Zambon Group's unique one-dose-only urinary antibiotic, marketed under the trademark Monuril (R).  Forest will co-develop and co-promote the Zambon product.
    The agreement, encompassing licensing, supply, development, and co- promotion rights is the first in a network of U.S. partnerships planned by the Zambon Group.  On the signing of the agreement, Daniel Sher, M.D., Zambon Corporation President & CEO, remarked that "Monuril will be our company's vanguard product in the U.S.  As such, it will set the stage for physicians' expectations about future innovations they can expect from Zambon Group research."
    Dr. Sher also commented on the competitive advantage of Zambon's new partnership: "The U.S. urinary antibiotic market is a very competitive one and with our new arrangement with Forest Laboratories, Zambon will have two strong competitive advantages.  "First, Monuril's unique one- dose-only regimen will avoid the significant patient compliance problems experienced by our competitors.  Second, the alliance with Forest backs this novel product with an established marketing and field sales team that is well known for their drive and effectiveness in reaching physicians.  Forest will enhance our own marketing efforts to assure significant market penetration for Monuril  and high awareness of Zambon as a sophisticated research company."
    Monuril has just been approved for marketing in the United Kingdom and Germany, and is already marketed in eight countries in Europe and South America.  The annual U.S. Market for urinary anti-infectives is approximately $350 million.  Phase III clinical trials of Monuril are well underway in the U.S. and the NDA filing is currently planned for late 1992.
    Zambon Corporation has also filed 2 other INDs:  ibopamine--- a new treatment for heart failure, and n-acetylcysteine for the treatment of AIDS.  By the end of the year Zambon will also file a third IND for a new, more rapidly absorbed form of ibuprofen.  Co-development partners will be sought for each of these products.
    Zambon Group is an Italian-based, research intensive multinational pharmaceutical firm.  The group develops and manufactures human and veterinary healthcare products, hospital devices, fine chemicals and vision products which it markets in most countries of the free world directly or through license.
    -0-                       11/21/91
    /CONTACT:  Herbert Grossman, chairman of Zambon, 201-896-2200/
    (FRX) CO:  Zambon Corporation; Forest Laboratories ST:  New Jersey, New York IN:  MTC SU:  LIC KD -- NY106 -- 6104 11/21/91 17:16 EST
COPYRIGHT 1991 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1991 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 21, 1991
Words:440
Previous Article:LUFKIN INDUSTRIES ANNOUNCES RECEIPT OF EXPORT ORDERS
Next Article:CMS/DATA CORPORATION BOARD OF DIRECTORS ADOPTS RIGHTS PLAN
Topics:


Related Articles
FOREST LICENSES U.S. RIGHTS TO FOSFOMYCIN TROMETAMOL FROM ZAMBON GROUP
FOREST LABORATORIES LICENSES ESTRADIOL TRANSDERMAL PATCH FROM ETHICAL PHARMACEUTICALS
FOREST LABORATORIES FILES NEW DRUG APPLICATION FOR SINGLE DOSE ANTIBIOTIC TO TREAT URINARY TRACT INFECTION
FDA Approves First One-Time, One-Dose Treatment for Uncomplicated Urinary Tract Infection
Sheffield Pharmaceuticals Regains Worldwide Rights to Premaire(TM) Delivery System From Zambon Group.
Newron and Zambon Group Sign Collaboration to Develop Novel Treatments for Pain Conditions.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters